IMMUNOHISTOCHEMISTRY, P53

The IHC – P53 test is an immunohistochemistry-based diagnostic assay used to detect p53 protein expression in tissue samples. P53 is a tumor suppressor protein that plays a critical role in regulating cell growth, DNA repair, and programmed cell death (apoptosis). Abnormal expression or mutation of the p53 gene is commonly associated with the development and progression of many cancers.

This test is widely used in pathology and oncology to evaluate tumor behavior, assess malignancy potential, and support cancer diagnosis. Abnormal p53 staining patterns may indicate genetic mutations linked to aggressive tumor growth and poor prognosis.

Benefits of the Test

• Helps assess tumor aggressiveness
• Supports diagnosis of various cancers
• Assists in evaluating abnormal cell proliferation
• Provides prognostic information in oncology
• Helps guide treatment planning and cancer management

Why Doctors Recommend This Test

Doctors recommend the IHC P53 test when evaluating suspected malignant tumors or cancer progression. It is commonly used in:

• Breast cancer evaluation
• Colorectal cancer diagnosis
• Lung cancer pathology studies
• Ovarian and gynecological tumor assessment
• Head and neck cancer investigations

P53 testing is frequently included in immunohistochemistry panels along with markers such as Ki-67, HER2, ER, PR, and cytokeratins for comprehensive tumor profiling.

Preparation Before Test

No special preparation is required for the patient. Important points include:

• The test is performed on a biopsy or surgical tissue sample
• No fasting or medication restrictions are needed
• Previous pathology reports and imaging studies may support interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on tissue processing and laboratory workflow.

Who Should Take This Test

• Patients with suspected malignant tumors
• Individuals undergoing cancer biopsy evaluation
• Cases requiring tumor grading and prognosis assessment
• Patients with recurrent or aggressive cancers
• Oncology patients requiring immunohistochemistry profiling

The IHC P53 test is an essential diagnostic tool in modern oncology and pathology. By identifying abnormal p53 protein expression, it helps clinicians understand tumor behavior, confirm diagnosis, and plan personalized treatment strategies.